J-Pharma Co., Ltd. (TSE: 520A)
Health Care · Biotechnology · JP
¥286.00
-1.38% today · -59.1% 1Y
J-Pharma Co., Ltd. (TSE: 520A) operates in the Biotechnology industry within the Health Care sector. The company is valued at $32.32M and employs 16 people.
Over the last twelve months the share price has lost 59.1%, trading between 260.00 and 809.00.
520A price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.32M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -195.08
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- ¥809.00
- 52-week low
- ¥260.00
- Avg volume (3M)
- —
- Shares outstanding
- 17.98M
- Employees
- 16
- Next earnings
- —
About J-Pharma Co., Ltd.
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
- Founded
- 2005
- Listed since
- Mar 25, 2026
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.